ncx-4040 and Melanoma

ncx-4040 has been researched along with Melanoma* in 1 studies

Other Studies

1 other study(ies) available for ncx-4040 and Melanoma

Article	Year
Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. Journal of medicinal chemistry, 2019, 07-25, Volume: 62, Issue:14 When using selective estrogen receptor modulators (SERMs) in cancer therapy, adverse effects such as endothelial dysfunction have to be considered. Estrogens and, consequently, SERMs regulate the synthesis of vasoactive nitric oxide ( Topics: Alkenes; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Human Umbilical Vein Endothelial Cells; Humans; Melanoma; Nitric Oxide Donors; Selective Estrogen Receptor Modulators; Therapeutic Index	2019

Article

Year

Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.

Journal of medicinal chemistry, 2019, 07-25, Volume: 62, Issue:14

When using selective estrogen receptor modulators (SERMs) in cancer therapy, adverse effects such as endothelial dysfunction have to be considered. Estrogens and, consequently, SERMs regulate the synthesis of vasoactive nitric oxide (

Topics: Alkenes; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Human Umbilical Vein Endothelial Cells; Humans; Melanoma; Nitric Oxide Donors; Selective Estrogen Receptor Modulators; Therapeutic Index

2019